The Role of Ferroptosis in Women's Health and Diseases

Abstract

Currently, there are many diseases worldwide that seriously affect women's health. Among these, gestational disorders and female cancers such as ovarian cancer are particularly notable for their high morbidity and mortality rates. Over the past decade, ferroptosis, a distinct form of programmed cell death primarily driven by iron-dependent phospholipid peroxidation, has been implicated in the pathogenesis of various female-related diseases. Despite many studies individually reporting that ferroptosis plays a crucial pathogenic role in common female disorders, there has yet to be a systematic overview addressing the mechanisms linking ferroptosis with women's health and disease. Thus, we herein provide a comprehensive review of the relationship between cellular pathways of ferroptosis and women's health and disease and describe the current progress of targeted therapy for ferroptosis. Following a succinct introduction to the disease, we summarize the regulatory role of ferroptosis in women's health and its implications for disease progression, with the aim of facilitating a clearer understanding of the relationship between ferroptosis and women's health. Finally, we discuss the emerging challenges and opportunities presented by various agonists or inhibitors targeting ferroptosis as potential therapeutic strategies for female-related diseases, providing additional protective approaches contributing to female health.

Keywords

ferroptosis / gynecological diseases / mechanism / obstetric diseases / targeted therapy

References

[1] S. J. Dixon, J. A. Olzmann, “The Cell Biology of Ferroptosis,” Nature Reviews Molecular Cell Biology 25, no. 6 (2024): 424-442.

[2] D. Tang, X. Chen, R. Kang, G. Kroemer, “Ferroptosis: Molecular Mechanisms and Health Implications,” Cell Research 31, no. 2 (2021): 107-125.

[3] X. Chen, R. Kang, G. Kroemer, D. Tang, “Organelle-Specific Regulation of Ferroptosis,” Cell Death and Differentiation 28, no. 10 (2021): 2843-2856.

[4] F. Peiyin, W. Yuxian, Z. Jiali, X. Jian, “Research Progress of Ferroptosis in Female Infertility,” Journal of Ovarian Research 17, no. 1 (2024): 183.

[5] N. Ma, M. Zhang, J. Hu, Z. Wei, S. Zhang, “Daphnetin Induces Ferroptosis in Ovarian Cancer by Inhibiting NAD(P)H:Quinone Oxidoreductase 1 (NQO1),” Phytomedicine 132 (2024): 155876.

[6] X. Zhou, M. Nie, X. Xin, et al., “RAB17 promotes Endometrial Cancer Progression by Inhibiting TFRC-Dependent Ferroptosis,” Cell Death & Disease 15, no. 9 (2024): 655.

[7] J. Jin, Z. Fan, Y. Long, et al., “Matrine Induces Ferroptosis in Cervical Cancer Through Activation of piezo1 Channel,” Phytomedicine 122 (2024): 155165.

[8] L. Yang, H. Wang, X. Yang, et al., “Auranofin Mitigates Systemic Iron Overload and Induces Ferroptosis via Distinct Mechanisms,” Signal Transduction Target Therapy 5, no. 1 (2020): 138.

[9] X. Zhou, H. Wang, B. Yan, et al., “Ferroptosis in Cardiovascular Diseases and Ferroptosis-Related Intervention Approaches,” (2024).

[10] L. Zhu, J. Zhou, C. Yu, et al., “Unraveling the Molecular Regulation of Ferroptosis in Respiratory Diseases,” Journal of Inflammation Research 17 (2024): 2531-2546.

[11] L. Du, Y. Wu, Z. Fan, et al., “The Role of Ferroptosis in Nervous System Disorders,” Journal of Integrative Neuroscience 22, no. 1 (2023): 19.

[12] Y. Song, et al., “The Role of Ferroptosis in Digestive System Cancer,” Oncology Letters 18, no. 3 (2019): 2159-2164.

[13] Z. Zhang, R. Yu, Q. Shi, et al., “COX15 Deficiency Causes Oocyte Ferroptosis,” PNAS 121, no. 45 (2024): e2406174121.

[14] S. Xiang, W. Yan, X. Ren, J. Feng, X. Zu, “Role of Ferroptosis and Ferroptosis-related Long Non-Coding RNA in Breast Cancer,” Cellular & Molecular Biology Letters 29, no. 1 (2024): 40.

[15] J. Torres-Torres, et al., “Cellular and Molecular Pathophysiology of Gestational Diabetes,” International Journal of Molecular Sciences, no. 21 (2024): 25.

[16] Q. Zhang, X. Yuan, X. Luan, et al., “GLUT1 exacerbates Trophoblast Ferroptosis by Modulating AMPK/ACC Mediated Lipid Metabolism and Promotes Gestational Diabetes Mellitus Associated Fetal Growth Restriction,” Molecular Medicine 30, no. 1 (2024): 257.

[17] L. B. Pontel, A. Bueno-Costa, A. E. Morellato, J. Carvalho Santos, G. Roué, M. Esteller, “Acute Lymphoblastic Leukemia Necessitates GSH-dependent Ferroptosis Defenses to Overcome FSP1-epigenetic Silencing,” Redox Biology 55 (2022): 102408.

[18] J. Luo, Y. Li, Y. Li, et al., “Reversing Ferroptosis Resistance in Breast Cancer via Tailored Lipid and Iron Presentation,” ACS Nano 17, no. 24 (2023): 25257-25268.

[19] Y. Wang, M. Hu, J. Cao, et al., “ACSL4 and Polyunsaturated Lipids Support Metastatic Extravasation and Colonization,” Cell 188, no. 2 (2025): 412-429.e27.

[20] Y. Lai, Y. Zhang, H. Zhang, et al., “Modified Shoutai Pill Inhibited Ferroptosis to Alleviate Recurrent Pregnancy Loss,” Journal of Ethnopharmacology 319, no. Pt 2 (2024): 117028.

[21] P. K. Morgan, G. Pernes, K. Huynh, et al., “A Lipid Atlas of human and Mouse Immune Cells Provides Insights Into Ferroptosis Susceptibility,” Nature Cell Biology 26, no. 4 (2024): 645-659.

[22] B. Qiu, F. Zandkarimi, C. T. Bezjian, et al., “Phospholipids With Two Polyunsaturated Fatty Acyl Tails Promote Ferroptosis,” Cell 187, no. 5 (2024): 1177-1190.e18.

[23] L. Liu, J. Pang, D. Qin, et al., “Deubiquitinase OTUD5 as a Novel Protector Against 4-HNE-Triggered Ferroptosis in Myocardial Ischemia/Reperfusion Injury,” Adv Sci (Weinh) 10, no. 28 (2023): e2301852.

[24] S. J. Dixon, B. R. Stockwell, “The Role of Iron and Reactive Oxygen Species in Cell Death,” Nature Chemical Biology 10, no. 1 (2014): 9-17.

[25] W. S. Yang, R. Sriramaratnam, M. E. Welsch, et al., “Regulation of Ferroptotic Cancer Cell Death by GPX4,” Cell 156, no. 1-2 (2014): 317-331.

[26] X. Lin, Q. Zhang, Q. Li, et al., “Upregulation of CoQ Shifts Ferroptosis Dependence From GPX4 to FSP1 in Acquired Radioresistance,” Drug Resistance Updates 73 (2024): 101032.

[27] X. Chen, J. Li, R. Kang, D. J. Klionsky, D. Tang, “Ferroptosis: Machinery and Regulation,” Autophagy 17, no. 9 (2021): 2054-2081.

[28] N. J. Dar, U. John, N. Bano, S. Khan, S. A. Bhat, “Oxytosis/Ferroptosis in Neurodegeneration: The Underlying Role of Master Regulator Glutathione Peroxidase 4 (GPX4),” Molecular Neurobiology 61, no. 3 (2024): 1507-1526.

[29] B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir, et al., “Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease,” Cell 171, no. 2 (2017): 273-285.

[30] I. Costa, D. J. Barbosa, S. Benfeito, et al., “Molecular Mechanisms of Ferroptosis and Their Involvement in Brain Diseases,” Pharmacology & Therapeutics 244 (2023): 108373.

[31] P. Koppula, L. Zhuang, B. Gan, “Cystine Transporter SLC7A11/xCT in Cancer: Ferroptosis, Nutrient Dependency, and Cancer Therapy,” Protein Cell 12, no. 8 (2021): 599-620.

[32] M. Soula, R. A. Weber, O. Zilka, et al., “Metabolic Determinants of Cancer Cell Sensitivity to Canonical Ferroptosis Inducers,” Nature Chemical Biology 16, no. 12 (2020): 1351-1360.

[33] V. A. N. Kraft, C. T. Bezjian, S. Pfeiffer, et al., “GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis Through Lipid Remodeling,” ACS Central Science 6, no. 1 (2020): 41-53.

[34] C. Mao, X. Liu, Y. Zhang, et al., “DHODH-mediated Ferroptosis Defence Is a Targetable Vulnerability in Cancer,” Nature 593, no. 7860 (2021): 586-590.

[35] S. Doll, F. P. Freitas, R. Shah, et al., “FSP1 is a Glutathione-independent Ferroptosis Suppressor,” Nature 575, no. 7784 (2019): 693-698.

[36] M. Gao, K. Fan, Y. Chen, G. Zhang, J. Chen, Y. Zhang, “Understanding the Mechanistic Regulation of Ferroptosis in Cancer: The Gene Matters,” Journal of Genetics and Genomics 49, no. 10 (2022): 913-926.

[37] K. Bersuker, J. M. Hendricks, Z. Li, et al., “The CoQ Oxidoreductase FSP1 Acts Parallel to GPX4 to Inhibit Ferroptosis,” Nature 575, no. 7784 (2019): 688-692.

[38] C. Wang, C. Chen, J. Zhou, et al., “DHODH Alleviates Heart Failure via the Modulation of CoQ-Related Ferroptotic Inhibition,” Frontiers in Bioscience (Landmark Ed) 29, no. 7 (2024): 267.

[39] J. Wang, N. Wu, M. Peng, et al., “Ferritinophagy: Research Advance and Clinical Significance in Cancers,” Cell Death Discovery 9, no. 1 (2023): 463.

[40] J. Liu, M. Yang, R. Kang, D. J. Klionsky, D. Tang, “Autophagic Degradation of the Circadian Clock Regulator Promotes Ferroptosis,” Autophagy 15, no. 11 (2019): 2033-2035.

[41] Y. Bai, L. Meng, L. Han, et al., “Lipid Storage and Lipophagy Regulates Ferroptosis,” Biochemical and Biophysical Research Communications 508, no. 4 (2019): 997-1003.

[42] C. A. Chen, D. Wang, Y. Yu, et al., “Legumain Promotes Tubular Ferroptosis by Facilitating Chaperone-Mediated Autophagy of GPX4 in AKI,” Cell Death & Disease 12, no. 1 (2021): 65.

[43] M. Fritsch, S. D. Günther, R. Schwarzer, et al., “Caspase-8 Is the Molecular Switch for Apoptosis, Necroptosis and Pyroptosis,” Nature 575, no. 7784 (2019): 683-687.

[44] K. E. Mcelhanon, C. Bose, R. Sharma, L. Wu, Y. C. Awasthi, S. P. Singh, “Gsta4 Null Mouse Embryonic Fibroblasts Exhibit Enhanced Sensitivity to Oxidants: Role of 4-Hydroxynonenal in Oxidant Toxicity,” Open Journal of Apoptosis 2, no. 1 (2013).

[45] B. R. Stockwell, “Ferroptosis Turns 10: Emerging Mechanisms, Physiological Functions, and Therapeutic Applications,” Cell 185, no. 14 (2022): 2401-2421.

[46] M. M. Gaschler, F. Hu, H. Feng, A. Linkermann, W. Min, B. R. Stockwell, “Determination of the Subcellular Localization and Mechanism of Action of Ferrostatins in Suppressing Ferroptosis,” ACS Chemical Biology 13, no. 4 (2018): 1013-1020.

[47] H. Feng, K. Schorpp, J. Jin, et al., “Transferrin Receptor Is a Specific Ferroptosis Marker,” Cell Reports 30, no. 10 (2020): 3411-3423.e7.

[48] E. Maltepe, S. J. Fisher, “Placenta: The Forgotten Organ,” Annual Review of Cell and Developmental Biology 31 (2015): 523-52.

[49] Y. Sun, M. Sha, Y. Qin, et al., “Bisphenol A Induces Placental Ferroptosis and Fetal Growth Restriction via the YAP/TAZ-ferritinophagy Axis,” Free Radical Biology and Medicine 213 (2024): 524-540.

[50] J. Dong, Y. Hu, S. Liu, et al., “Arsenic Induces Ferroptosis in HTR-8/SVneo Cells and Placental Damage,” Science of the Total Environment 955 (2024): 176885.

[51] K. Kajiwara, O. Beharier, C. P. Chng, et al., “Ferroptosis Induces Membrane Blebbing in Placental Trophoblasts,” Journal of Cell Science, no. 5 (2022): 135.

[52] O. Beharier, V. A. Tyurin, J. P. Goff, et al., “PLA2G6 guards Placental Trophoblasts Against Ferroptotic Injury,” PNAS 117, no. 44 (2020): 27319-27328.

[53] E. C. Johns, F. C. Denison, J. E. Norman, R. M. Reynolds, Gestational Diabetes Mellitus: Mechanisms, Treatment, and Complications. Trends in Endocrinology and Metabolism, 2018. 29(11): 743-754.

[54] J. Yu, J. Ren, Y. Ren, et al., “Using Metabolomics and Proteomics to Identify the Potential Urine Biomarkers for Prediction and Diagnosis of Gestational Diabetes,” EBioMedicine 101 (2024): 105008.

[55] A. Sweeting, W. Hannah, H. Backman, et al., “Epidemiology and Management of Gestational Diabetes,” Lancet 404, no. 10448 (2024): 175-192.

[56] M. Jin, et al., “Micro-RNAs in Human Placenta: Tiny Molecules, Immense Power,” Molecules (Basel, Switzerland), no. 18 (2022): 27.

[57] L. Liu, F. Yan, H. Yan, Z. Wang, “Impact of Iron Supplementation on Gestational Diabetes Mellitus: A Literature Review,” Diabetes, Obesity & Metabolism 25, no. 2 (2023): 342-353.

[58] S. Rawal, S. N. Hinkle, W. Bao, et al., “A Longitudinal Study of Iron Status During Pregnancy and the Risk of Gestational Diabetes: Findings From a Prospective, Multiracial Cohort,” Diabetologia 60, no. 2 (2017): 249-257.

[59] WHO Guidelines Approved by the Guidelines Review Committee, in Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women. 2012, World Health Organization Copyright © 2012, World Health Organization: Geneva.

[60] Y. Feng, Q. Feng, H. Qu, et al., “Stress Adaptation Is Associated With Insulin Resistance in Women With Gestational Diabetes Mellitus,” Nutrition & Diabetes 10, no. 1 (2020): 4.

[61] T. T. Lao, P. L. Chan, K. F. Tam, “Gestational Diabetes Mellitus in the Last Trimester—a Feature of Maternal Iron Excess?” Diabetic Medicine 18, no. 3 (2001): 218-23.

[62] S. Hershenfeld, C. Ye, A. J. Hanley, P. W. Connelly, B. Zinman, R. Retnakaran, “Serum Ferritin and Glucose Homeostasis in Women with Recent Gestational Diabetes,” The Canadian Journal of Diabetes 43, no. 8 (2019): 567-572.

[63] X. Zhang, M. Wu, C. Zhong, et al., “Association Between Maternal Plasma Ferritin Concentration, Iron Supplement Use, and the Risk of Gestational Diabetes: A Prospective Cohort Study,” American Journal of Clinical Nutrition 114, no. 3 (2021): 1100-1106.

[64] D. Han, L. Jiang, X. Gu, et al., “SIRT3 deficiency Is Resistant to Autophagy-dependent Ferroptosis by Inhibiting the AMPK/mTOR Pathway and Promoting GPX4 Levels,” Journal of Cellular Physiology 235, no. 11 (2020): 8839-8851.

[65] A. Galano, R. J. Reiter, “Melatonin and Its Metabolites vs Oxidative Stress: From Individual Actions to Collective Protection,” Journal of Pineal Research 65, no. 1 (2018): e12514.

[66] Y. Zheng, Q. Hu, J. Wu, “Adiponectin Ameliorates Placental Injury in Gestational Diabetes Mice by Correcting Fatty Acid Oxidation/Peroxide Imbalance-Induced Ferroptosis via Restoration of CPT-1 Activity,” Endocrine 75, no. 3 (2022): 781-793.

[67] E. Dimitriadis, D. L. Rolnik, W. Zhou, et al., “Pre-Eclampsia,” Nature Reviews Disease Primers 9, no. 1 (2023): 8.

[68] L. Sun, M. Shi, J. Wang, et al., “Overexpressed Trophoblast Glycoprotein Contributes to Preeclampsia Development by Inducing Abnormal Trophoblast Migration and Invasion toward the Uterine Spiral Artery,” Hypertension 81, no. 7 (2024): 1524-1536.

[69] Y. T. Chiang, K. M. Seow, K. H. Chen, “The Pathophysiological, Genetic, and Hormonal Changes in Preeclampsia: A Systematic Review of the Molecular Mechanisms,” International Journal of Molecular Sciences, no. 8 (2024): 25.

[70] M. Jin, S. Xu, B. Cao, et al., “Regulator of G Protein Signaling 2 Is Inhibited by Hypoxia-Inducible Factor-1α/E1A Binding Protein P300 Complex Upon Hypoxia in human Preeclampsia,” International Journal of Biochemistry & Cell Biology 147 (2022): 106211.

[71] L. Li, C. Zhu, Q. Xu, et al., “ALKBH1 contributes to Renal Cell Carcinoma Progression by Reducing N6-methyladenine of GPR137,” European Journal of Clinical Investigation 53, no. 7 (2023): e13986.

[72] M. Jin, B. Cao, C. Lin, et al., “Tianma Gouteng Decoction Exerts Pregnancy-Protective Effects against Preeclampsia via Regulation of Oxidative Stress and no Signaling,” Frontiers in Pharmacology 13 (2022): 849074.

[73] K. E. Gumilar, B. Priangga, C.-H. Lu, E. G. Dachlan, M. Tan, “Iron Metabolism and Ferroptosis: A Pathway for Understanding Preeclampsia,” Biomedicine & Pharmacotherapy 167 (2023): 115565.

[74] M. A. Ortega, L. M. Garcia-Puente, O. Fraile-Martinez, et al., “Oxidative Stress, Lipid Peroxidation and Ferroptosis Are Major Pathophysiological Signatures in the Placental Tissue of Women With Late-Onset Preeclampsia,” Antioxidants (Basel), no. 5 (2024): 13.

[75] L. Zhang, S. Bi, Y. Liang, et al., “Integrated Metabolomic and Lipidomic Analysis in the Placenta of Preeclampsia,” Frontiers in Physiology 13 (2022): 807583.

[76] X. Zhou, T.-L. Han, H. Chen, P. N. Baker, H. Qi, H. Zhang, “Impaired Mitochondrial Fusion, Autophagy, Biogenesis and Dysregulated Lipid Metabolism Is Associated With Preeclampsia,” Experimental Cell Research 359, no. 1 (2017): 195-204.

[77] T. Liao, X. Xu, X. Ye, J. Yan, “DJ-1 Upregulates the Nrf2/GPX4 Signal Pathway to Inhibit Trophoblast Ferroptosis in the Pathogenesis of Preeclampsia,” Scientific Reports 12, no. 1 (2022): 2934.

[78] S. W. Ng, S. G. Norwitz, E. R. Norwitz, “The Impact of Iron Overload and Ferroptosis on Reproductive Disorders in Humans: Implications for Preeclampsia,” International Journal of Molecular Sciences, no. 13 (2019): 20.

[79] Y. Wang, S. W. Walsh, “Aspirin Inhibits both Lipid Peroxides and Thromboxane in Preeclamptic Placentas,” Free Radical Biology and Medicine 18, no. 3 (1995): 585-91.

[80] R. Liu, G. Yang, M. Bao, et al., “STAMBPL1 promotes Breast Cancer Cell Resistance to Cisplatin Partially by Stabilizing MKP-1 Expression,” Oncogene 41, no. 16 (2022): 2265-2274.

[81] H. Zhang, Y. He, J.-X. Wang, et al., “miR-30-5p-mediated Ferroptosis of Trophoblasts Is Implicated in the Pathogenesis of Preeclampsia,” Redox Biology 29 (2020): 101402.

[82] X. Yang, Y. Ding, L. Sun, et al., “Ferritin Light Chain Deficiency-induced Ferroptosis Is Involved in Preeclampsia Pathophysiology by Disturbing Uterine Spiral Artery Remodelling,” Redox Biology 58 (2022): 102555.

[83] Y. Wang, L. Zhang, X. Zhou, “Activation of Nrf2 Signaling Protects Hypoxia-Induced HTR-8/SVneo Cells Against Ferroptosis,” Journal of Obstetrics and Gynaecology Research 47, no. 11 (2021): 3797-3806.

[84] N. R. Abu-Rustum, C. M. Yashar, R. Arend, et al., “NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024,” Journal of the National Comprehensive Cancer Network: JNCCN 21, no. 12 (2023): 1224-1233.

[85] C. Park, S. Alahari, J. Ausman, et al., “Placental Hypoxia-Induced Ferroptosis Drives Vascular Damage in Preeclampsia,” Circulation Research (2025).

[86] L. Li, H. He, Z. Zheng, X. Zhao, “MLL1 promotes Placental Trophoblast Ferroptosis and Aggravates Preeclampsia Symptoms Through Epigenetic Regulation of RBM15/TRIM72/ADAM9 Axis,” Biology Direct 19, no. 1 (2024): 133.

[87] W. Lai, L. Yu, Y. Deng, “PPARγ Alleviates Preeclampsia Development by Regulating Lipid Metabolism and Ferroptosis,” Communications Biology 7, no. 1 (2024): 429.

[88] A. M. F. Woolner, E. A. Raja, S. Bhattacharya, M. E. Black, “Risk of Spontaneous Preterm Birth Elevated After First Cesarean Delivery at Full Dilatation: A Retrospective Cohort Study of Over 30,000 Women,” American Journal of Obstetrics and Gynecology 230, no. 3 (2024): 358.e1-358.e13.

[89] R. L. Goldenberg, J. F. Culhane, J. D. Iams, R. Romero, “Epidemiology and Causes of Preterm Birth,” Lancet 371, no. 9606 (2008): 75-84.

[90] J. J. Hirst, H. K. Palliser, C. Pavy, J. C. Shaw, R. A. Moloney, “Neurosteroid Replacement Approaches for Improving Outcomes After Compromised Pregnancies and Preterm Birth,” Frontiers in Neuroendocrinology 76 (2025): 101169.

[91] G. Natarajan, S. Shankaran, “Short- and Long-Term Outcomes of Moderate and Late Preterm Infants,” American Journal of Perinatology 33, no. 3 (2016): 305-17.

[92] C. Zhu, Q. Yang, Q. Xu, Y. Song, C. Tang, “The Role of Heart and Neural Crest Derivatives-Expressed Protein Factors in Pregnancy,” Biochimica Et Biophysica Acta-Molecular Basis of Disease 1871, no. 3 (2024): 167639.

[93] S. Quenby, I. D. Gallos, R. K. Dhillon-Smith, et al., “Miscarriage Matters: The Epidemiological, Physical, Psychological, and Economic Costs of Early Pregnancy Loss,” Lancet 397, no. 10285 (2021): 1658-1667.

[94] F. Zhu, D. Noordermeer, E. Aribas, M. Bos, E. Boersma, M. Kavousi, “Metabolic Disorders Mediate the Relation of Miscarriage With Cardiovascular Diseases,” European Journal of Preventive Cardiology 31, no. 3 (2024): 330-336.

[95] S. Wan, X. Wang, W. Chen, et al., “Exposure to High Dose of Polystyrene Nanoplastics Causes Trophoblast Cell Apoptosis and Induces Miscarriage,” Particle and Fibre Toxicology 21, no. 1 (2024): 13.

[96] L. Meihe, G. Shan, K. Minchao, et al., “The Ferroptosis-NLRP1 Inflammasome: The Vicious Cycle of an Adverse Pregnancy,” Frontiers in Cell and Developmental Biology 9 (2021): 707959.

[97] X.-H. Wang, S. Xu, X.-Y. Zhou, et al., “Low Chorionic Villous Succinate Accumulation Associates With Recurrent Spontaneous Abortion Risk,” Nature Communications 12, no. 1 (2021): 3428.

[98] H. Guan, P. Zhou, Y. Qi, H. Huang, J. Wang, X. Liu, “Cigarette Smoke-Induced Trophoblast Cell Ferroptosis in Rat Placenta and the Effects of L-arginine Intervention,” Ecotoxicology and Environmental Safety 243 (2022): 114015.

[99] P. Zhou, F. Jin, S. Yao, et al., “Mitochondrial Mayhem: How Cigarette Smoke Induces Placental Dysfunction Through MMS19 Degradation,” Ecotoxicology and Environmental Safety 290 (2025): 117728.

[100] R. X. Bai, Z. Y. Tang, “Long Non-Coding RNA H19 Regulates Bcl-2, Bax and Phospholipid Hydroperoxide Glutathione Peroxidase Expression in Spontaneous Abortion,” Experimental and Therapeutic Medicine 21, no. 1 (2021): 41.

[101] P. Tian, Z. Xu, J. Guo, et al., “Hypoxia Causes Trophoblast Cell Ferroptosis to Induce Miscarriage Through Lnc-HZ06/HIF1α-SUMO/NCOA4 Axis,” Redox Biology 70 (2024): 103073.

[102] L. Webber, et al., “ESHRE Guideline: Management of Women With Premature Ovarian Insufficiency,” Human Reproduction 31, no. 5 (2016): 926-37.

[103] M. De Vos, P. Devroey, B. C. Fauser, “Primary Ovarian Insufficiency,” Lancet 376, no. 9744 (2010): 911-21.

[104] Z. Nash, M. Davies, “Premature Ovarian Insufficiency,” Bmj 384 (2024): e077469.

[105] L. R. Schover, “Premature Ovarian Failure and Its Consequences: Vasomotor Symptoms, Sexuality, and Fertility,” Journal of Clinical Oncology 26, no. 5 (2008): 753-8.

[106] M S. Chesnokov, A R. Mamedova, B. Zhivotovsky, G S. Kopeina, “A Matter of New Life and Cell Death: Programmed Cell Death in the Mammalian Ovary,” Journal of Biomedical Science 31, no. 1 (2024): 31.

[107] F. Wang, Y. Liu, F. Ni, et al., “BNC1 deficiency-triggered Ferroptosis Through the NF2-YAP Pathway Induces Primary Ovarian Insufficiency,” Nature Communications 13, no. 1 (2022): 5871.

[108] Y. Lai, F. Zeng, Z. Chen, et al., Shikonin Could Be Used to Treat Tubal Pregnancy via Enhancing Ferroptosis Sensitivity. Drug Design, Development and Therapy, 2022. 16: 2083-2099.

[109] A P. Bielfeld, S. J. Pour, G. Poschmann, K. Stühler, J.-S. Krüssel, D M. Baston-Büst, “A Proteome Approach Reveals Differences Between Fertile Women and Patients With Repeated Implantation Failure on Endometrial Level⁻Does hCG Render the Endometrium of RIF Patients?” International Journal of Molecular Sciences 20, no. 2 (2019).

[110] Y. Fang, D. Fang, “Comprehensive Analysis of Placental Gene-expression Profiles and Identification of EGFR-mediated Autophagy and Ferroptosis Suppression in Intrahepatic Cholestasis of Pregnancy,” Gene 834 (2022): 146594.

[111] G. Lei, L. Zhuang, B. Gan, “The Roles of Ferroptosis in Cancer: Tumor Suppression, Tumor Microenvironment, and Therapeutic Interventions,” Cancer Cell 42, no. 4 (2024): 513-534.

[112] Y.-B. Zuo, Y.-F. Zhang, R. Zhang, et al., “Ferroptosis in Cancer Progression: Role of Noncoding RNAs,” International Journal of Biological Science 18, no. 5 (2022): 1829-1843.

[113] L. Zhao, X. Zhou, F. Xie, et al., “Ferroptosis in Cancer and Cancer Immunotherapy,” Cancer Community (Lond) 42, no. 2 (2022): 88-116.

[114] A. Anandhan, M. Dodson, A. Shakya, et al., “NRF2 controls Iron Homeostasis and Ferroptosis Through HERC2 and VAMP8,” Science Advances 9, no. 5 (2023): eade9585.

[115] Y. Luo, Y. Chen, H. Jin, et al., “The Suppression of Cervical Cancer Ferroptosis by Macrophages: The Attenuation of ALOX15 in Cancer Cells by Macrophages-Derived Exosomes,” Acta Pharmaceutica Sinica B 13, no. 6 (2023): 2645-2662.

[116] Y. Wang, C. Wang, X. Guan, et al., “PRMT3-Mediated Arginine Methylation of METTL14 Promotes Malignant Progression and Treatment Resistance in Endometrial Carcinoma,” Advanced Science (Weinh) 10, no. 36 (2023): e2303812.

[117] H. Li, P. Yang, J. Wang, et al., “HLF Regulates Ferroptosis, Development and Chemoresistance of Triple-negative Breast Cancer by Activating Tumor Cell-macrophage Crosstalk,” Journal of Hematology & Oncology 15, no. 1 (2022): 2.

[118] Y.-Y. Li, Y.-Q Peng, Y.-X. Yang, et al., “Baicalein Improves the Symptoms of Polycystic Ovary Syndrome by Mitigating Oxidative Stress and Ferroptosis in the Ovary and Gravid Placenta,” Phytomedicine 128 (2024): 155423.

[119] K R. Cho, I.-M. Shih, “Ovarian Cancer,” Annu Rev Pathol 4 (2009): 287-313.

[120] D K. Armstrong, R D. Alvarez, F J. Backes, et al., “NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022,” Journal of the National Comprehensive Cancer Network: JNCCN 20, no. 9 (2022): 972-980.

[121] Z. X. Chong, “Roles of miRNAs in Regulating Ovarian Cancer Stemness,” Biochimica et Biophysica Acta - Reviews on Cancer 1879, no. 6 (2024): 189191.

[122] C. Tang, L. Li, C. Zhu, et al., “GPR137-RAB8A activation Promotes Ovarian Cancer Development via the Hedgehog Pathway,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 22.

[123] S. Xu, C. Zhu, Q. Xu, et al., “ARID1A restrains EMT and Stemness of Ovarian Cancer Cells Through the Hippo Pathway,” International Journal of Oncology 65, no. 2 (2024).

[124] L. Kuroki, S. R. Guntupalli, “Treatment of Epithelial Ovarian Cancer,” Bmj 371 (2020): m3773.

[125] X. Sun, S. Wang, J. Gai, et al., “SIRT5 Promotes Cisplatin Resistance in Ovarian Cancer by Suppressing DNA Damage in a ROS-Dependent Manner via Regulation of the Nrf2/HO-1 Pathway,” Frontiers in oncology 9 (2019): 754.

[126] Y. Wang, G. Zhao, S. Condello, et al., “Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis,” Cancer Research 81, no. 2 (2021): 384-399.

[127] Y. Zhang, M. Xia, Z. Zhou, et al., “p53 Promoted Ferroptosis in Ovarian Cancer Cells Treated With Human Serum Incubated-Superparamagnetic Iron Oxides,” Int J Nanomedicine 16 (2021): 283-296.

[128] W. Novera, Z.-W. Lee, D. S. Nin, et al., “Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma via Oxidative Stress and Iron-Sulfur Cluster Biogenesis Deficit,” Antioxid Redox Signaling 33, no. 17 (2020): 1191-1208.

[129] H. Miao, H. Meng, Y. Zhang, T. Chen, L. Zhang, W. Cheng, “FSP1 inhibition Enhances Olaparib Sensitivity in BRCA-proficient Ovarian Cancer Patients via a Nonferroptosis Mechanism,” Cell Death and Differentiation 31, no. 4 (2024): 497-510.

[130] D. W. Chan, M. M. Yung, Y.-S. Chan, et al., “MAP30 Protein From Momordica charantia Is Therapeutic and Has Synergic Activity With Cisplatin Against Ovarian Cancer in Vivo by Altering Metabolism and Inducing Ferroptosis,” Pharmacological Research 161 (2020): 105157.

[131] Q. Cheng, L. Bao, M. Li, K. Chang, X. Yi, “Erastin Synergizes With Cisplatin via Ferroptosis to Inhibit Ovarian Cancer Growth in Vitro and in Vivo,” Journal of Obstetrics and Gynaecology Research 47, no. 7 (2021): 2481-2491.

[132] T. Hong, G. Lei, X. Chen, et al., “PARP Inhibition Promotes Ferroptosis via Repressing SLC7A11 and Synergizes With Ferroptosis Inducers in BRCA-Proficient Ovarian Cancer,” Redox Biology 42 (2021): 101928.

[133] Y. Wu, C. Jia, W. Liu, et al., “Sodium Citrate Targeting Ca(2+)/CAMKK2 Pathway Exhibits Anti-Tumor Activity Through Inducing Apoptosis and Ferroptosis in Ovarian Cancer,” Journal of Advanced Research (2024).

[134] Z. Yu, H. He, Y. Chen, Q. Ji, M. Sun, “A Novel Ferroptosis Related Gene Signature Is Associated With Prognosis in Patients With Ovarian Serous Cystadenocarcinoma,” Scientific Reports 11, no. 1 (2021): 11486.

[135] R. Chen, et al., “Upregulated Expression of CYBRD1 Predicts Poor Prognosis of Patients With Ovarian Cancer,” Journal of Oncology 2021 (2021): 7548406.

[136] B. Chai, Y. Wu, H. Yang, et al., “Tau Aggregation-Dependent Lipid Peroxide Accumulation Driven by the hsa_circ_0001546/14-3-3/CAMK2D/Tau Complex Inhibits Epithelial Ovarian Cancer Peritoneal Metastasis,” Advanced Science (Weinh) 11, no. 23 (2024): e2310134.

[137] M. Lizano, A. Carrillo‑García, E. De La Cruz‑Hernández, L. Castro‑Muñoz, A. Contreras‑Paredes, “Promising Predictive Molecular Biomarkers for Cervical Cancer (Review),” International Journal of Molecular Medicine 53, no. 6 (2024).

[138] Q. Xu, M. Yao, C. Tang, “RGS2 and Female Common Diseases: A Guard of Women's Health,” Journal of Translational Medicine 21, no. 1 (2023): 583.

[139] K. Matsuo, H. Machida, R S. Mandelbaum, I. Konishi, M. Mikami, “Validation of the 2018 FIGO Cervical Cancer Staging System,” Gynecologic Oncology 152, no. 1 (2019): 87-93.

[140] A. Mohamud, C. Høgdall, T. Schnack, “Prognostic Value of the 2018 FIGO Staging System for Cervical Cancer,” Gynecologic Oncology 165, no. 3 (2022): 506-513.

[141] C. Wang, J. Zeng, L.-J. Li, M. Xue, S.-L. He, “Cdc25A inhibits Autophagy-mediated Ferroptosis by Upregulating ErbB2 Through PKM2 Dephosphorylation in Cervical Cancer Cells,” Cell Death & Disease 12, no. 11 (2021): 1055.

[142] X. Wang, Y. Ji, J. Qi, et al., “Mitochondrial Carrier 1 (MTCH1) Governs Ferroptosis by Triggering the FoxO1-GPX4 Axis-Mediated Retrograde Signaling in Cervical Cancer Cells,” Cell Death & Disease 14, no. 8 (2023): 508.

[143] R.-R. Ye, B.-C. Chen, J.-J. Lu, X.-R. Ma, R.-T. Li, “Phosphorescent Rhenium(I) Complexes Conjugated With Artesunate: Mitochondrial Targeting and Apoptosis-ferroptosis Dual Induction,” Journal of Inorganic Biochemistry 223 (2021): 111537.

[144] J. Xiaofei, S. Mingqing, S. Miao, et al., “Oleanolic Acid Inhibits Cervical Cancer HeLa Cell Proliferation Through Modulation of the ACSL4 Ferroptosis Signaling Pathway,” Biochemical and Biophysical Research Communications 545 (2021): 81-88.

[145] R. Ou, S. Lu, L. Wang, et al., “Circular RNA circLMO1 Suppresses Cervical Cancer Growth and Metastasis by Triggering miR-4291/ACSL4-Mediated Ferroptosis,” Frontiers in Oncology 12 (2022): 858598.

[146] Z. Jiang, J. Li, W. Feng, Y. Sun, J. Bu, “A Ferroptosis-Related lncRNA Model to Enhance the Predicted Value of Cervical Cancer,” Journal of Oncology 2022 (2022): 6080049.

[147] X. Qi, Y. Fu, J. Sheng, et al., “A Novel Ferroptosis-related Gene Signature for Predicting Outcomes in Cervical Cancer,” Bioengineered 12, no. 1 (2021): 1813-1825.

[148] C. Xing, H. Yin, Z.-Y. Yao, X.-L. Xing, “Prognostic Signatures Based on Ferroptosis- and Immune-Related Genes for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma,” Frontiers in Oncology 11 (2021): 774558.

[149] Á. López-Janeiro, et al., “Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated With Cell Death and Cell Signaling,” Cancers (Basel) 13, no. 4 (2021).

[150] L. Tesfay, B T. Paul, A. Konstorum, et al., “Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells From Ferroptotic Cell Death,” Cancer Research 79, no. 20 (2019): 5355-5366.

[151] X. Zhang, W. Yan, X. Chen, et al., “Long-term 4-nonylphenol Exposure Drives Cervical Cell Malignancy Through MAPK-mediated Ferroptosis Inhibition,” Journal of Hazardous Materials 471 (2024): 134371.

[152] M. Feng, et al., “Triptolide Promotes Ferroptosis in Cervical Cancer Cell via NRF2/xCT/GPX4,” Phytotherapy Research (2024).

[153] H. Ye, X. Ding, X. Lv, et al., “KLF14 directly Downregulates the Expression of GPX4 to Exert Antitumor Effects by Promoting Ferroptosis in Cervical Cancer,” Journal of Translational Medicine 22, no. 1 (2024): 923.

[154] C. Mao, G. Lei, A. Horbath, et al., “Unraveling ETC Complex I Function in Ferroptosis Reveals a Potential Ferroptosis-Inducing Therapeutic Strategy for LKB1-Deficient Cancers,” Molecular Cell 84, no. 10 (2024): 1964-1979.

[155] E. J. Crosbie, S. J. Kitson, J. N. McAlpine, A. Mukhopadhyay, M. E. Powell, N. Singh, “Endometrial Cancer,” Lancet 399, no. 10333 (2022): 1412-1428.

[156] F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, I. Vergote, “Endometrial Cancer,” Lancet 366, no. 9484 (2005): 491-505.

[157] J A. How, A A. Jazaeri, S N. Westin, et al., “Translating Biological Insights Into Improved Management of Endometrial Cancer,” Nature reviews Clinical oncology 21, no. 11 (2024): 781-800.

[158] A. Jamieson, J. N. McAlpine, “Molecular Profiling of Endometrial Cancer from TCGA to Clinical Practice,” Journal of the National Comprehensive Cancer Network: JNCCN 21, no. 2 (2023): 210-216.

[159] Z. An, J. Wang, C. Li, C. Tang, “Signal Integrator Function of CXXC5 in Cancer,” Cell Communication and Signaling 23, no. 1 (2025): 25.

[160] C. Banz-Jansen, L. P. Helweg, B. Kaltschmidt, “Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?” International Journal of Molecular Sciences, no. 6 (2022): 23.

[161] eBioMedicine, Endometrial Cancer: Improving Management Among Increasing Incidence Rates. EBioMedicine, 2024. 103:105159.

[162] A. Salmon, A. Lebeau, S. Streel, et al., “Locally Advanced and Metastatic Endometrial Cancer: Current and Emerging Therapies,” Cancer Treatment Reviews 129 (2024): 102790.

[163] A. Sugiyama, T. Ohta, M. Obata, K. Takahashi, M. Seino, S. Nagase, “xCT Inhibitor Sulfasalazine Depletes Paclitaxel-resistant Tumor Cells Through Ferroptosis in Uterine Serous Carcinoma,” Oncology Letters 20, no. 3 (2020): 2689-2700.

[164] S.-J. Chen, J. Zhang, T. Zhou, et al., “Epigenetically Upregulated NSUN2 Confers Ferroptosis Resistance in Endometrial Cancer via M(5)C Modification of SLC7A11 mRNA,” Redox Biology 69 (2024): 102975.

[165] M. Zhang, T. Zhang, C. Song, et al., “Guizhi Fuling Capsule Ameliorates Endometrial Hyperplasia Through Promoting p62-Keap1-NRF2-Mediated Ferroptosis,” Journal of Ethnopharmacology 274 (2021): 114064.

[166] Y.-Y. Zhang, Z.-J. Ni, E. Elam, et al., “Juglone, a Novel Activator of Ferroptosis, Induces Cell Death in Endometrial Carcinoma Ishikawa Cells,” Food and Function 12, no. 11 (2021): 4947-4959.

[167] Y. Weijiao, L. Fuchun, C. Mengjie, et al., “Immune Infiltration and a Ferroptosis-Associated Gene Signature for Predicting the Prognosis of Patients With Endometrial Cancer,” Aging (Albany NY) 13, no. 12 (2021): 16713-16732.

[168] J. Liu, Y. Wang, H. Meng, Y. Yin, H. Zhu, T. Ni, “Identification of the Prognostic Signature Associated with Tumor Immune Microenvironment of Uterine Corpus Endometrial Carcinoma Based on Ferroptosis-Related Genes,” Frontiers in Cell and Developmental Biology 9 (2021): 735013.

[169] J. Yan, G. Ye, Y. Shao, “High Expression of the Ferroptosis-associated MGST1 Gene in Relation to Poor Outcome and Maladjusted Immune Cell Infiltration in Uterine Corpus Endometrial Carcinoma,” Journal of Clinical Laboratory Analysis 36, no. 4 (2022): e24317.

[170] J. Qin, X. Shao, L. Wu, H. Du, “Identification of the Ferroptosis-Associated Gene Signature to Predict the Prognostic Status of Endometrial Carcinoma Patients,” Computational and Mathematical Methods in Medicine 2021 (2021): 9954370.

[171] H. Wang, Y. Wu, S. Chen, M. Hou, Y. Yang, M. Xie, “Construction and Validation of a Ferroptosis-Related Prognostic Model for Endometrial Cancer,” Frontiers in Genetics 12 (2021): 729046.

[172] R. M. Marquardt, D. N. Tran, B. A. Lessey, M. S. Rahman, J.-W. Jeong, “Epigenetic Dysregulation in Endometriosis: Implications for Pathophysiology and Therapeutics,” Endocrine Reviews 44, no. 6 (2023): 1074-1095.

[173] S.-W. Ng, S G. Norwitz, H S. Taylor, E R. Norwitz, “Endometriosis: The Role of Iron Overload and Ferroptosis,” Reproductive Sciences 27, no. 7 (2020): 1383-1390.

[174] H. S. Taylor, A. M. Kotlyar, V. A. Flores, “Endometriosis Is a Chronic Systemic Disease: Clinical Challenges and Novel Innovations,” Lancet 397, no. 10276 (2021): 839-852.

[175] A. W. Horne, P. T. K. Saunders, “SnapShot: Endometriosis,” Cell 179, no. 7 (2019): 1677-1677.e1.

[176] C. Allaire, M. A. Bedaiwy, P. J. Yong, “Diagnosis and Management of Endometriosis,” Cmaj 195, no. 10 (2023): E363-e371.

[177] S. Li, Y. Zhou, Q. Huang, et al., “Iron Overload in Endometriosis Peritoneal Fluid Induces Early Embryo Ferroptosis Mediated by HMOX1,” Cell Death Discovery 7, no. 1 (2021): 355.

[178] Y. Li, X. Zeng, D. Lu, M. Yin, M. Shan, Y. Gao, “Erastin Induces Ferroptosis via Ferroportin-Mediated Iron Accumulation in Endometriosis,” Human Reproduction 36, no. 4 (2021): 951-964.

[179] G. Li, Y. Lin, Y. Zhang, et al., “Endometrial Stromal Cell Ferroptosis Promotes Angiogenesis in Endometriosis,” Cell Death Discov 8, no. 1 (2022): 29.

[180] Y. Wan, Y. Song, J. Chen, et al., “Upregulated Fibulin-1 Increased Endometrial Stromal Cell Viability and Migration by Repressing EFEMP1-Dependent Ferroptosis in Endometriosis,” BioMed Research International 2022 (2022): 4809415.

[181] Y. Y. Huang, et al., “Association Between the Genetic Variants of Glutathione Peroxidase 4 and Severity of Endometriosis,” International Journal of Environmental Research and Public Health, no. 14 (2020): 17.

[182] B. Li, H. Duan, S. Wang, Y. Li, “Ferroptosis Resistance Mechanisms in Endometriosis for Diagnostic Model Establishment,” Reproductive Biomedicine Online 43, no. 1 (2021): 127-138.

[183] S. Chen, X. Ma, Y. Liu, et al., “Creatine Promotes Endometriosis by Inducing Ferroptosis Resistance via Suppression of PrP,” Adv Sci (Weinh) 11, no. 38 (2024): e2403517.

[184] Z. Liang, Q. Wu, H. Wang, et al., “Silencing of lncRNA MALAT1 Facilitates Erastin-Induced Ferroptosis in Endometriosis Through miR-145-5p/MUC1 Signaling,” Cell Death Discov 8, no. 1 (2022): 190.

[185] E. Stener-Victorin, H. Teede, R J. Norman, et al., “Polycystic Ovary Syndrome,” Nature Reviews Disease Primers 10, no. 1 (2024): 27.

[186] H. Pastoor, A. Mousa, H. Bolt, et al., “Sexual Function in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis,” Human Reproduction Update 30, no. 3 (2024): 323-340.

[187] S. L. Robinson, E. H. Yeung, “Polycystic Ovary Syndrome and Preterm Birth-What's Going on?” Fertility and Sterility 115, no. 2 (2021): 326-327.

[188] V. Rodriguez Paris, X. Y. D. Wong, S. M. Solon-Biet, et al., “The Interplay Between PCOS Pathology and Diet on Gut Microbiota in a Mouse Model,” Gut Microbes 14, no. 1 (2022): 2085961.

[189] H. F. Escobar-Morreale, “Iron Metabolism and the Polycystic Ovary Syndrome,” Trends in Endocrinology and Metabolism 23, no. 10 (2012): 509-15.

[190] X. Li, Y. Lin, X. Cheng, et al., “Ovarian Ferroptosis Induced by Androgen Is Involved in Pathogenesis of PCOS,” Hum Reprod Open 2024, no. 2 (2024): hoae013.

[191] D. Zhang, S. Yi, B. Cai, et al., “Involvement of Ferroptosis in the Granulosa Cells Proliferation of PCOS Through the circRHBG/miR-515/SLC7A11 Axis,” Annals of Translational Medicine 9, no. 16 (2021): 1348.

[192] J. Zou, Y. Li, N. Liao, et al., “Identification of Key Genes Associated With Polycystic Ovary Syndrome (PCOS) and Ovarian Cancer Using an Integrated Bioinformatics Analysis,” Journal of Ovarian Research 15, no. 1 (2022): 30.

[193] W. Tan, F. Dai, D. Yang, et al., “MiR-93-5p Promotes Granulosa Cell Apoptosis and Ferroptosis by the NF-kB Signaling Pathway in Polycystic Ovary Syndrome,” Frontiers in Immunology 13 (2022): 967151.

[194] X. Zhang, Z. Huang, Z. Xie, et al., “Homocysteine Induces Oxidative Stress and Ferroptosis of Nucleus Pulposus via Enhancing Methylation of GPX4,” Free Radical Biology and Medicine 160 (2020): 552-565.

[195] Q. Shi, R. Liu, L. Chen, “Ferroptosis Inhibitor Ferrostatin‑1 Alleviates Homocysteine‑Induced Ovarian Granulosa Cell Injury by Regulating TET Activity and DNA Methylation,” Molecular Medicine Reports 25, no. 4 (2022).

[196] M. Hu, Y. Zhang, L. Lu, et al., “Overactivation of the Androgen Receptor Exacerbates Gravid Uterine Ferroptosis via Interaction With and Suppression of the NRF2 Defense Signaling Pathway,” FEBS Letters 596, no. 6 (2022): 806-825.

[197] Y. Xie, W. Hou, X. Song, et al., “Ferroptosis: Process and Function,” Cell Death and Differentiation 23, no. 3 (2016): 369-79.

[198] Y. Zhang, W. Zhao, H. Xu, et al., “Hyperandrogenism and Insulin Resistance-induced Fetal Loss: Evidence for Placental Mitochondrial Abnormalities and Elevated Reactive Oxygen Species Production in Pregnant Rats That Mimic the Clinical Features of Polycystic Ovary Syndrome,” The Journal of Physiology 597, no. 15 (2019): 3927-3950.

[199] Y. Sui, X. Geng, Z. Wang, J. Zhang, Y. Yang, Z. Meng, “Targeting the Regulation of Iron Homeostasis as a Potential Therapeutic Strategy for Nonalcoholic Fatty Liver Disease,” Metabolism 157 (2024): 155953.

[200] M. Hu, Y. Zhang, S. Ma, et al., “Suppression of Uterine and Placental Ferroptosis by N-acetylcysteine in a Rat Model of Polycystic Ovary Syndrome,” Molecular Human Reproduction 27, no. 12 (2021).

[201] H. Yang, S. Chen, S. Yin, Q. Ding, “Nuciferine Protects Hyperandrogen-injured Ovarian Granulosa Cells by Inhibiting Ferroptosis via SOX2-Mediated Activation of the SLC7A11/GPX4 Axis,” Journal of Applied Toxicology 45, no. 2 (2025): 256-265.

[202] Y. Liang, H. Zhang, X. Song, Q. Yang, “Metastatic Heterogeneity of Breast Cancer: Molecular Mechanism and Potential Therapeutic Targets,” Seminars in Cancer Biology 60 (2020): 14-27.

[203] M R. Lloyd, K. Jhaveri, K. Kalinsky, A. Bardia, S A. Wander, “Precision Therapeutics and Emerging Strategies for HR-positive Metastatic Breast Cancer,” Nature Reviews Clinical Oncology 21, no. 10 (2024): 743-761.

[204] L. Li, Q. Xu, C. Tang, “RGS Proteins and Their Roles in Cancer: Friend or Foe?” Cancer Cell International 23, no. 1 (2023): 81.

[205] L. Li, Z. An, C. Lin, Q. Xu, C. Tang, “An Update on Regulation and Function of G Protein-Coupled Receptors in Cancer: A Promising Strategy for Cancer Therapy,” Biochimica et Biophysica Acta - Reviews on Cancer 1880, no. 2 (2025): 189266.

[206] F. Bray, J. Ferlay, I. Soerjomataram, R L. Siegel, L A. Torre, A. Jemal, “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 68, no. 6 (2018): 394-424.

[207] Y. Liang, Y. Wang, Y. Zhang, et al., “HSPB1 facilitates Chemoresistance Through Inhibiting Ferroptotic Cancer Cell Death and Regulating NF-κB Signaling Pathway in Breast Cancer,” Cell Death & Disease 14, no. 7 (2023): 434.

[208] M. Shen, S. Cao, X. Long, et al., “DNAJC12 causes Breast Cancer Chemotherapy Resistance by Repressing Doxorubicin-Induced Ferroptosis and Apoptosis via Activation of AKT,” Redox Biology 70 (2024): 103035.

[209] G. Hu, R A. Chong, Q. Yang, et al., “MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer,” Cancer Cell 15, no. 1 (2009): 9-20.

[210] G. Lei, C. Mao, A D. Horbath, et al., “BRCA1-mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-deficient Cancers,” Cancer Discovery (2024).

[211] J. Yang, Y. Zhou, S. Xie, et al., “Metformin Induces Ferroptosis by Inhibiting UFMylation of SLC7A11 in Breast Cancer,” Journal of Experimental & Clinical Cancer Research 40, no. 1 (2021): 206.

[212] L. Zhao, L. Jin, B. Yang, “Diosmetin Alleviates S. aureus-Induced Mastitis by Inhibiting SIRT1/GPX4 Mediated Ferroptosis,” Life Sciences 331 (2023): 122060.

[213] J. Zhang, T. Su, Y. Fan, C. Cheng, L. Xu, LiTian, “Spotlight on Iron Overload and Ferroptosis: Research Progress in Female Infertility,” Life Sciences 340 (2024): 122370.

[214] Q. Zhu, S. Yao, Z. Ye, et al., “Ferroptosis Contributes to Endometrial Fibrosis in Intrauterine Adhesions,” Free Radical Biology and Medicine 205 (2023): 151-162.

[215] Y. Sun, M. Sha, Y. Qin, et al., “Bisphenol A Induces Placental Ferroptosis and Fetal Growth Restriction via the YAP/TAZ-Ferritinophagy Axis,” Free Radical Biology and Medicine 211 (2024): 127-144.

[216] L. Cao, J. Liu, C. Ye, Y. Hu, R. Qin, “Caffeic Acid Inhibits Staphylococcus aureus-Induced Endometritis Through Regulating AMPKα/mTOR/HIF-1α Signalling Pathway,” Journal of Cellular and Molecular Medicine 28, no. 20 (2024): e70175.

[217] T. Wang, T. Xiong, Y. Yang, et al., “Estradiol-Mediated Small GTP-Binding Protein GDP Dissociation Stimulator Induction Contributes to Sex Differences in Resilience to Ferroptosis in Takotsubo Syndrome,” Redox Biology 68 (2023): 102961.

[218] S. Sun, J. Shen, J. Jiang, F. Wang, J. Min, “Targeting Ferroptosis Opens New Avenues for the Development of Novel Therapeutics,” Signal Transduction and Target Therapy 8, no. 1 (2023): 372.

[219] Y. Fang, X. Chen, Q. Tan, H. Zhou, J. Xu, Q. Gu, “Inhibiting Ferroptosis Through Disrupting the NCOA4-FTH1 Interaction: A New Mechanism of Action,” ACS Cent Sci, no. 6 (2021): 980-989.

[220] Y. Chen, P. Zhang, W. Chen, G. Chen, “Ferroptosis Mediated DSS-induced Ulcerative Colitis Associated With Nrf2/HO-1 Signaling Pathway,” Immunology Letters 225 (2020): 9-15.

[221] S. Sui, J. Zhang, S. Xu, Q. Wang, P. Wang, D. Pang, “Ferritinophagy Is Required for the Induction of Ferroptosis by the Bromodomain Protein BRD4 Inhibitor (+)-JQ1 in Cancer Cells,” Cell Death & Disease 10, no. 5 (2019): 331.

[222] X. Fang, H. Wang, D. Han, et al., “Ferroptosis as a Target for Protection Against Cardiomyopathy,” PNAS 116, no. 7 (2019): 2672-2680.

[223] X. Sun, Z. Ou, R. Chen, et al., “Activation of the p62-Keap1-NRF2 Pathway Protects Against Ferroptosis in Hepatocellular Carcinoma Cells,” Hepatology 63, no. 1 (2016): 173-84.

[224] B. Hassannia, B. Wiernicki, I. Ingold, et al., “Nano-targeted Induction of Dual Ferroptotic Mechanisms Eradicates High-risk Neuroblastoma,” Journal of Clinical Investigation 128, no. 8 (2018): 3341-3355.

[225] L. Wang, H. Cai, Y. Hu, et al., “A Pharmacological Probe Identifies Cystathionine β-synthase as a New Negative Regulator for Ferroptosis,” Cell Death & Disease 9, no. 10 (2018): 1005.

[226] S. Wang, W. Liu, J. Wang, X. Bai, “Curculigoside Inhibits Ferroptosis in Ulcerative Colitis Through the Induction of GPX4,” Life Sciences 259 (2020): 118356.

[227] N. Yamada, T. Karasawa, T. Wakiya, et al., “Iron Overload as a Risk Factor for Hepatic Ischemia-reperfusion Injury in Liver Transplantation: Potential Role of Ferroptosis,” American Journal of Transplantation 20, no. 6 (2020): 1606-1618.

[228] Y. Zhang, H. Tan, J D. Daniels, et al., “Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model,” Cell Chemical Biology 26, no. 5 (2019): 623-633.e9.

[229] J.-J. Lee, G.-P. Chang-Chien, S. Lin, et al., “5-Lipoxygenase Inhibition Protects Retinal Pigment Epithelium From Sodium Iodate-Induced Ferroptosis and Prevents Retinal Degeneration,” Oxidative Medicine and Cellular Longevity 2022 (2022): 1792894.

[230] L. Sleire, B. S. Skeie, I. A. Netland, et al., “Drug Repurposing: Sulfasalazine Sensitizes Gliomas to Gamma Knife Radiosurgery by Blocking Cystine Uptake Through System Xc-, Leading to Glutathione Depletion,” Oncogene 34, no. 49 (2015): 5951-9.

[231] X.-J. Zhang, Y.-X. Ji, X. Cheng, et al., “A Small Molecule Targeting ALOX12-ACC1 Ameliorates Nonalcoholic Steatohepatitis in Mice and Macaques,” Science Translational Medicine 13, no. 624 (2021): eabg8116.

[232] S. Doll, B. Proneth, Y. Y. Tyurina, et al., “ACSL4 dictates Ferroptosis Sensitivity by Shaping Cellular Lipid Composition,” Nature Chemical Biology 13, no. 1 (2017): 91-98.

[233] M. Fujita, A. Hasegawa, M. Yamamori, N. Okamura, “In Vitro and in Vivo Cytotoxicity of Troglitazone in Pancreatic Cancer,” Journal of Experimental & Clinical Cancer Research 36, no. 1 (2017): 91.

[234] X. Shan, S. Li, B. Sun, et al., “Ferroptosis-driven Nanotherapeutics for Cancer Treatment,” Journal of Control Release 319 (2020): 322-332.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.